Last reviewed · How we verify
Betamethasone Valerate (BETAMETHASONE VALERATE)
Betamethasone Valerate is a corticosteroid medication that targets the glucocorticoid receptor to treat various skin conditions. Originally developed by Schering, it is now owned by Fougera Pharms Inc and has been FDA-approved since 1967 for conditions such as atopic dermatitis, contact dermatitis, and plaque psoriasis. As a small molecule corticosteroid, it is available as a generic medication with multiple manufacturers. Betamethasone Valerate is off-patent and has no active Orange Book patents. It is used to reduce inflammation and suppress the immune system in the treatment of various skin conditions.
At a glance
| Generic name | BETAMETHASONE VALERATE |
|---|---|
| Sponsor | Fougera Pharms Inc |
| Drug class | Corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
| First approval | 1967 |
Approved indications
- Atopic dermatitis
- Contact dermatitis
- Dermatosis of scalp
- Discoid lupus erythematosus
- Eruption of skin
- Granuloma annulare
- Lichen simplex chronicus
- Plaque psoriasis
- Primary cutaneous T-cell lymphoma
- Pruritus ani
- Pruritus of genital organs
- Scalp psoriasis
- Seborrheic dermatitis
Common side effects
- Skin atrophy
- Secondary infection
- Allergic contact dermatitis
- Maceration of the skin
- Burning
- Itching
- Irritation
- Dryness
- Folliculitis
- Hypertrichosis
- Acneiform eruptions
- Hypopigmentation
Key clinical trials
- Evaluation the Topical Apremilast Nanoformulation in Treatment of Localized Plaque Psoriasis (NA)
- Single Dose of Antenatal Corticosteroids for Pregnancies at Risk of Preterm Delivery (SNACS) (PHASE4)
- Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation (PHASE2,PHASE3)
- New Topical Treatment in Plaque Psoriasis (NA)
- Skin bioMARkers for Atopic Eczema Therapy Evaluation (PHASE2)
- Metformin Repurposing in Oral Submucous Fibrosis: Unveiling In Vitro Signaling Pathways, Progressing to Clinical Trial (PHASE1,PHASE2)
- A Psoriasis Plaque Test Trial With LEO 90100 Compared to Betesil® in Patients With Psoriasis Vulgaris (PHASE2)
- Efficacy and Safety of Fucicort® Lipid Cream Compared to Combination Treatment With Fucidin® Cream Followed by Betamethasone (Lianbang Beisong®) Cream and Fucicort® Lipid Cream Vehicle in Clinically Infected Atopic Dermatitis/Eczema (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Betamethasone Valerate CI brief — competitive landscape report
- Betamethasone Valerate updates RSS · CI watch RSS
- Fougera Pharms Inc portfolio CI